140 related articles for article (PubMed ID: 36870379)
1. JAK inhibition for CD3
Faguer S; Groh M; Vergez F; Hunault-Berger M; Duployez N; Renaudineau Y; Paul C; Lefevre G; Kahn JE
Clin Immunol; 2023 Jun; 251():109275. PubMed ID: 36870379
[TBL] [Abstract][Full Text] [Related]
2. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.
Lefèvre G; Copin MC; Staumont-Sallé D; Avenel-Audran M; Aubert H; Taieb A; Salles G; Maisonneuve H; Ghomari K; Ackerman F; Legrand F; Baruchel A; Launay D; Terriou L; Leclech C; Khouatra C; Morati-Hafsaoui C; Labalette M; Borie R; Cotton F; Gouellec NL; Morschhauser F; Trauet J; Roche-Lestienne C; Capron M; Hatron PY; Prin L; Kahn JE;
Medicine (Baltimore); 2014 Oct; 93(17):255-266. PubMed ID: 25398061
[TBL] [Abstract][Full Text] [Related]
3. The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES).
Helbig G; Wichary R; Razny M; Rodzaj M; Wozniczka K; Dziaczkowska-Suszek J; Kyrcz-Krzemien S
Scand J Immunol; 2010 Oct; 72(4):372-3. PubMed ID: 20883323
[No Abstract] [Full Text] [Related]
4. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
5. CD3
Carpentier C; Schandené L; Dewispelaere L; Heimann P; Cogan E; Roufosse F
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2426-2439.e7. PubMed ID: 33545400
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilia Associated With CD3
Carpentier C; Verbanck S; Schandené L; Heimann P; Trépant AL; Cogan E; Roufosse F
Front Immunol; 2020; 11():1765. PubMed ID: 32849632
[No Abstract] [Full Text] [Related]
7. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways.
Ravoet M; Sibille C; Gu C; Libin M; Haibe-Kains B; Sotiriou C; Goldman M; Roufosse F; Willard-Gallo K
Blood; 2009 Oct; 114(14):2969-83. PubMed ID: 19608752
[TBL] [Abstract][Full Text] [Related]
8. Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution.
Hu Z; Wang W; Thakral B; Chen Z; Estrov Z; Bueso-Ramos CE; Verstovsek S; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2021 May; 100(3):352-360. PubMed ID: 32157815
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome.
Tabata R; Tabata C; Katashima Y; Yasumizu R
Int Immunopharmacol; 2013 Aug; 16(4):488-91. PubMed ID: 23669338
[TBL] [Abstract][Full Text] [Related]
10. What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review.
Shi Y; Wang C
Clin Immunol; 2022 Apr; 237():108982. PubMed ID: 35307610
[TBL] [Abstract][Full Text] [Related]
11. Targeting CCR4 with mogamulizumab in refractory CD3
Ledoult E; Groh M; Meresse B; Dubois R; Trauet J; Toussaint E; Delbeke M; Hachulla E; Terriou L; De Masson A; Vasseur M; Labalette M; Launay D; Kahn JE; Lefevre G
Haematologica; 2024 Jun; 109(6):1984-1988. PubMed ID: 38328856
[No Abstract] [Full Text] [Related]
12. Eosinophils affect functions of in vitro-activated human CD3-CD4+ T cells.
Harfi I; Schandené L; Dremier S; Roufosse F
J Transl Med; 2013 May; 11():112. PubMed ID: 23642304
[TBL] [Abstract][Full Text] [Related]
13. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome.
Ravoet M; Sibille C; Roufosse F; Duvillier H; Sotiriou C; Schandené L; Martiat P; Goldman M; Willard-Gallo KE
Haematologica; 2005 Jun; 90(6):753-65. PubMed ID: 15951288
[TBL] [Abstract][Full Text] [Related]
14. Korean Adolescent Patient with Manifestations of Lymphocyte Variant Hypereosinophilic Syndrome and Episodic Angioedema with Eosinophilia, Treated with Reslizumab.
Jue JH; Shim YJ; Park S; Kim DH; Jung HR
Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):215-218. PubMed ID: 35490275
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin is an effective and well-tolerated therapy in CD3
Baulier G; Asli B; Galicier L; Fieschi C; Brice P; Malphettes M
J Allergy Clin Immunol Pract; 2019; 7(8):2885-2887.e1. PubMed ID: 31078759
[No Abstract] [Full Text] [Related]
16. Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome.
Willard-Gallo KE; Badran BM; Ravoet M; Zerghe A; Burny A; Martiat P; Goldman M; Roufosse F; Sibille C
Exp Hematol; 2005 Oct; 33(10):1147-59. PubMed ID: 16219537
[TBL] [Abstract][Full Text] [Related]
17. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes.
Bank I; Amariglio N; Reshef A; Hardan I; Confino Y; Trau H; Shtrasburg S; Langevitz P; Monselise Y; Shalit M; Rechavi G
Leuk Lymphoma; 2001 Jun; 42(1-2):123-33. PubMed ID: 11699199
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilia associated with clonal T-cell proliferation.
Kitano K; Ichikawa N; Shimodaira S; Ito T; Ishida F; Kiyosawa K
Leuk Lymphoma; 1997 Oct; 27(3-4):335-42. PubMed ID: 9402331
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
King B; Lee AI; Choi J
J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
[No Abstract] [Full Text] [Related]
20. [Lymphocytic variant of the hypereosinophilic syndrome].
Roldán Montaud A; Citores Sánchez MJ; Perales Fraile I; Masip Marzá V; Bellas Menéndez C; Vargas Núñez JA
Rev Clin Esp; 2009 Jun; 209(6):303-8. PubMed ID: 19635254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
